Meeting
2012 ASCO Annual Meeting
Phase I trial of ixabepilone and vorinostat in metastatic breast cancer.
Authors
Thehang H. Luu
City of Hope, Duarte, CA
Thehang H. Luu , Suzette Blanchard , Jan Hendrik Beumer , Bean N. Anyang , George Somlo , Joanne E. Mortimer , Arti Hurria , Lixin Yang , Yun Yen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01084057
Citation
J Clin Oncol 30, 2012 (suppl; abstr 1070)
DOI
10.1200/jco.2012.30.15_suppl.1070
Abstract #
1070
Poster Bd #
23E
Abstract Disclosures
Similar Posters
Poster
2013 Breast Cancer Symposium
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2013 ASCO Annual Meeting
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
First Author: Edward Samuel James
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel
Poster
2017 ASCO Annual Meeting
Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.
First Author: Shubham Pant